EIF4A3B Antibody

What is EIF4A3 and why is it important in molecular biology research?

EIF4A3 (eukaryotic translation initiation factor 4A, isoform 3) is a DEAD-box family ATP-dependent RNA helicase that functions as a core component of the exon junction complex (EJC). It plays crucial roles in post-transcriptional gene regulation, including mRNA splicing, nonsense-mediated mRNA decay (NMD), and RNA metabolism . EIF4A3 is particularly important in research because it:

• Acts as a nucleocytoplasmic shuttling protein found in both nucleus and cytoplasm

• Participates in splicing-dependent multiprotein complexes that control mRNA quality

• Maintains expression of significant selenoproteins under physiological conditions

• Has been implicated in multiple human cancers, including glioblastoma, hepatocellular carcinoma, pancreatic cancer, and ovarian cancer

Understanding EIF4A3 function provides crucial insights into fundamental RNA processing mechanisms and potential therapeutic targets for various diseases.

What types of EIF4A3 antibodies are available for research and what are their specific applications?

Several well-validated EIF4A3 antibodies are available for research purposes, with varying applications and specificities:

EIF4A3 antibodies have been extensively used in published applications including:

• Western blotting (38+ publications)

• Immunofluorescence (10+ publications)

• Immunohistochemistry (5+ publications)

• RNA immunoprecipitation (15+ publications)

• Co-immunoprecipitation (4+ publications)

• Knockdown/knockout validation studies (6+ publications)

When selecting an EIF4A3 antibody, researchers should consider the specific application, target species, and whether the experiment requires detection of specific protein interactions or modifications.

How should I design experiments to study EIF4A3 function in RNA processing and splicing events?

Designing robust experiments to study EIF4A3's role in RNA processing requires careful consideration of multiple factors:

Recommended experimental approach:

• Establish clear baseline measurements: Begin with RNA-seq analysis to establish baseline splicing patterns in your model system before manipulation of EIF4A3 levels .

• Consider knockdown approach: Use siRNA-mediated knockdown (at least two different siRNAs targeting EIF4A3) to avoid off-target effects. Wang et al. demonstrated that knockdown of EJC core proteins, including EIF4A3, causes transcript-wide changes in alternative splicing .

• Include appropriate controls: Always include knockdown of other EJC components (Y14, Magoh) and unrelated proteins (such as GFP) as controls to differentiate EIF4A3-specific effects from general EJC-mediated functions .

• Validate knockdown efficiency: Verify protein depletion by Western blot using validated antibodies (dilution 1:1000-1:4000) and mRNA reduction by qRT-PCR .

• Analyze splicing changes: Employ RNA-seq with sufficient depth (>20 million reads) and replicate experiments at least in duplicate to identify statistically significant splicing alterations .

• Validate key splicing events: Confirm RNA-seq findings with RT-PCR for selected targets, especially exon-skipping events that may be functionally relevant .

• Functional rescue experiments: Perform rescue experiments with wild-type EIF4A3 expression to confirm specificity of observed phenotypes .

Remember that manipulation of EIF4A3 levels will affect multiple RNA processing pathways simultaneously, so careful experimental design and data interpretation are essential.

What are the optimal conditions for using EIF4A3 antibodies in Western blotting applications?

To achieve optimal results with EIF4A3 antibodies in Western blotting, follow these methodological guidelines:

Sample preparation:

• Extract proteins from cells/tissues using RIPA buffer containing protease inhibitors

• For nuclear proteins, consider using specialized nuclear extraction protocols

• Load 20-40 μg of total protein per lane

Electrophoresis and transfer conditions:

• Use 10-12% SDS-PAGE gels for optimal resolution of EIF4A3 (calculated MW: 47 kDa)

• Transfer to PVDF membranes at 100V for 60-90 minutes in cold transfer buffer

Blocking and antibody incubation:

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary EIF4A3 antibody at 1:1000-1:4000 dilution overnight at 4°C

• Wash 3× with TBST, 5 minutes each

• Incubate with HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

Detection:

• Use enhanced chemiluminescence for detection

• Expected band is at 47 kDa

Validation controls:

• Positive controls: A549 cells, HEK-293 cells, HeLa cells, MCF-7 cells, and HepG2 cells all show consistent EIF4A3 expression

• Negative control: Lysate from cells with confirmed EIF4A3 knockdown

This protocol consistently detects EIF4A3 as a distinct 47 kDa band in multiple cell types and tissue samples from human, mouse, and rat sources .

How can I properly design immunofluorescence experiments using EIF4A3 antibodies?

Successful immunofluorescence experiments with EIF4A3 antibodies require attention to several critical methodological details:

Cell preparation:

• Culture cells on coverslips until 60-80% confluent

• Fix with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

Immunostaining procedure:

• Block with 1% BSA, 5% normal goat serum in PBST for 1 hour

• Incubate with primary EIF4A3 antibody at 1:10-1:100 dilution overnight at 4°C

• Wash 3× with PBS, 5 minutes each

• Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

• Counterstain nuclei with DAPI (1 μg/ml) for 5 minutes

• Mount with anti-fade mounting medium

Expected localization pattern:

• EIF4A3 exhibits predominantly nuclear localization with some cytoplasmic distribution

• In the nucleus, expect a diffuse nucleoplasmic pattern with exclusion from nucleoli

• Under specific conditions (such as cell stress), distribution patterns may change

Controls and validation:

• Include siRNA-mediated EIF4A3 knockdown cells as negative controls

• Co-stain with markers for nuclear speckles (SC35) to verify localization pattern

• Validate specificity using two different antibodies recognizing different epitopes

MCF-7 cells have been validated as a reliable model for EIF4A3 immunofluorescence studies, showing clear nuclear localization patterns . The subcellular localization of EIF4A3 can change under certain conditions, such as autophagy induction, where it has been shown to affect TFEB nuclear translocation .

How does EIF4A3 function in autophagy regulation and what methodological approaches best capture this interaction?

Recent research has revealed that EIF4A3 plays a critical role in regulating autophagy through the TFEB-mediated transcriptional response. To effectively study this function:

Recommended methodological approach:

• Monitor autophagy markers: Assess LC3B lipidation (LC3-I to LC3-II conversion) by Western blot and quantify GFP-LC3B puncta formation by fluorescence microscopy in EIF4A3-depleted cells .

• Evaluate autophagic flux: Use Bafilomycin A1 treatment to block autophagosome-lysosome fusion and determine if EIF4A3 affects autophagosome formation or degradation rates.

• Analyze TFEB activation: Monitor TFEB phosphorylation status by Western blot (looking for electrophoretic shift) and nuclear translocation by immunofluorescence. Depletion of EIF4A3 leads to TFEB dephosphorylation and nuclear translocation .

• Assess TFEB target gene expression: Quantify mRNA levels of known TFEB targets using qRT-PCR after EIF4A3 knockdown. Research has shown that EIF4A3 knockdown upregulates multiple TFEB targets .

• Perform rescue experiments: Express exogenous EIF4A3 in depleted backgrounds to confirm specificity. Doxycycline-inducible expression systems have been successfully used for this purpose .

• Investigate mechanism: Analyze if EIF4A3 affects known TFEB regulators like GSK3B through alternative splicing. EIF4A3 depletion has been shown to cause exon-skipping in GSK3B transcripts, reducing its expression and activity .

This regulatory axis has significant implications for understanding autophagy regulation in both normal and disease states, particularly in cancer where EIF4A3 is frequently upregulated .

What are the most effective approaches for studying EIF4A3's role in viral replication and innate immunity?

EIF4A3 has been implicated in RNA virus replication and innate immune responses. To effectively investigate this function:

Experimental strategy:

• Viral infection models: Use established RNA virus systems like influenza A virus (IAV), Sendai virus (SeV), or vesicular stomatitis virus (VSV) in appropriate cell lines. These viruses have been validated as models for studying EIF4A3's impact on viral replication .

• Modulate EIF4A3 levels: Employ siRNA-mediated knockdown or overexpression systems. Ensure validation of knockdown efficiency by both Western blot and qRT-PCR .

• Measure viral replication: Quantify viral load through plaque assays, RT-qPCR of viral transcripts, or immunoblotting of viral proteins.

• Assess type I interferon responses: Use luciferase reporter assays with IFN-β promoter constructs to measure activation. Research has shown that overexpression of EIF4A3 reduces SeV-triggered IFN-β promoter activity in a dose-dependent manner .

• Evaluate downstream signaling: Monitor IRF3 phosphorylation, nuclear translocation, and binding to interferon-stimulated response elements (ISRE). EIF4A3 has been found to inhibit virus-triggered phosphorylation and nuclear translocation of IRF3 .

• Quantify interferon-stimulated genes (ISGs): Measure mRNA levels of IFN-β, ISGs (Mx1, ISG15, IFIT2, IFITM3, OAS3, OASL), and proinflammatory cytokines by qRT-PCR after viral stimulation .

• Investigate protein-protein interactions: Use co-immunoprecipitation to study interactions between EIF4A3 and key innate immune signaling components like TBK1 and IRF3. EIF4A3 and TBK1 have been shown to compete for binding to the same region of IRF3 .

Understanding EIF4A3's role in antiviral responses may provide insights into novel therapeutic strategies for viral infectious diseases.

How can I design experiments to investigate EIF4A3's functions in cancer progression?

To effectively study EIF4A3's roles in cancer progression, consider this comprehensive experimental approach:

Research strategy:

• Expression analysis in cancer tissues: Analyze EIF4A3 expression across cancer types using immunohistochemistry (IHC) at 1:20-1:200 dilution. The antibody has been validated for IHC in multiple human tissues including brain, kidney, heart, lung, ovary, spleen, and testis .

• Correlation with clinical parameters: Correlate EIF4A3 expression levels with clinicopathological features and patient outcomes using tissue microarrays and patient databases.

• Functional studies in cancer cell lines:

  • Conduct loss-of-function studies using siRNA or shRNA targeting EIF4A3

  • Perform gain-of-function experiments with overexpression constructs

  • Assess effects on proliferation, invasion, migration, and apoptosis

  • Evaluate anchorage-independent growth using soft agar colony formation assays

• Mechanistic investigations:

  • Identify cancer-specific RNA targets using RNA immunoprecipitation (RIP) followed by sequencing

  • Analyze alternative splicing changes upon EIF4A3 knockdown using RNA-seq

  • Examine interactions with cancer-relevant long non-coding RNAs

  • Investigate effects on oncogenic signaling pathways

• In vivo models:

  • Establish xenograft models with EIF4A3-modulated cancer cells

  • Monitor tumor growth, metastasis, and response to therapies

  • Consider patient-derived xenografts for translational relevance

• Therapeutic potential:

  • Test small molecule inhibitors of EIF4A3 in vitro and in vivo

  • Evaluate combination approaches with standard chemotherapies

  • Assess potential biomarker value for patient stratification

This approach has been validated in multiple cancer types including glioblastoma, hepatocellular carcinoma, pancreatic cancer, and ovarian cancer, where EIF4A3 has been shown to promote tumor growth .

What are common sources of experimental variability when working with EIF4A3 antibodies and how can they be addressed?

Researchers frequently encounter several sources of variability when working with EIF4A3 antibodies. Here are systematic approaches to identify and address these issues:

Common sources of variability and solutions:

• Antibody specificity concerns:

  • Problem: Cross-reactivity with other EIF4A family members (EIF4A1/EIF4A2)

  • Solution: Validate antibody specificity using lysates from EIF4A3 knockdown cells; always check the observed molecular weight (47 kDa for EIF4A3)

• Variable band patterns in Western blots:

  • Problem: Multiple bands or unexpected molecular weights

  • Solution: EIF4A3 should appear at 47 kDa; if seeing bands at different molecular weights, optimize extraction conditions and verify with positive control samples (HeLa, MCF-7, HepG2 cells all show consistent expression)

• Inconsistent immunofluorescence signals:

  • Problem: Weak nuclear staining or high background

  • Solution: Optimize fixation method (4% PFA recommended), increase permeabilization time, and use fresh antibody dilutions. MCF-7 cells provide reliable positive controls for IF applications

• Sample preparation issues:

  • Problem: Degraded EIF4A3 protein or inconsistent extraction

  • Solution: Use fresh protease inhibitors, maintain cold conditions during extraction, and process samples quickly. For nuclear proteins, specialized extraction protocols may be necessary

• Immunoprecipitation challenges:

  • Problem: Poor IP efficiency or high background

  • Solution: Optimize antibody concentration (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate), increase wash stringency, and pre-clear lysates thoroughly

• Batch-to-batch antibody variation:

  • Problem: Inconsistent results between antibody lots

  • Solution: Validate each new lot against previous successful experiments and maintain positive control samples for comparison

• RNA-protein interaction study issues:

  • Problem: Variable RIP efficiency

  • Solution: Optimize crosslinking conditions, ensure RNase-free environment, and validate RNA integrity post-immunoprecipitation

Maintaining detailed laboratory records of optimization parameters and successful protocols will help ensure reproducibility when working with EIF4A3 antibodies across different experimental applications.

How can I resolve contradictory results when studying EIF4A3 in different cell types or experimental systems?

When faced with contradictory results across different experimental systems, a systematic troubleshooting approach is essential:

Methodological resolution strategy:

• Cell type-specific regulation:

  • Issue: EIF4A3 may exhibit different functions in different cell types

  • Solution: Compare baseline expression levels across cell types using standardized Western blot protocols. Examine EIF4A3 interaction partners in each cell type using co-immunoprecipitation. Cell-specific post-translational modifications may account for functional differences

• Experimental condition variations:

  • Issue: Different culture conditions affect EIF4A3 function

  • Solution: Standardize culture conditions (serum concentration, cell density, passage number) across experiments. Document any variations in media formulations or supplements

• Knockdown efficiency differences:

  • Issue: Variable EIF4A3 depletion levels lead to different phenotypes

  • Solution: Quantify knockdown efficiency by both protein (Western blot) and mRNA (qRT-PCR) levels. Consider using multiple siRNAs and establishing stable knockdown cell lines for consistency

• Temporal dynamics:

  • Issue: EIF4A3-mediated effects may be time-dependent

  • Solution: Perform detailed time-course experiments after knockdown or overexpression. For example, track TFEB translocation and autophagy markers at multiple time points after EIF4A3 depletion

• Stress and stimulation variations:

  • Issue: EIF4A3 functions may be stress-responsive

  • Solution: Carefully control cellular stress levels. Document experimental handling procedures and minimize variations in temperature, pH, and exposure to light

• Experimental readout sensitivity:

  • Issue: Different detection methods yield conflicting results

  • Solution: Employ multiple independent techniques to measure the same parameter. For instance, assess autophagy by both Western blot for LC3B lipidation and microscopy for puncta formation

• Genetic background differences:

  • Issue: Underlying genetic variations affect EIF4A3 function

  • Solution: Sequence critical regions to identify potential polymorphisms, consider using isogenic cell lines, or perform rescue experiments with wild-type EIF4A3

By systematically addressing these potential sources of variation, researchers can reconcile contradictory results and develop a more nuanced understanding of context-dependent EIF4A3 functions.

What are emerging techniques and approaches that will advance our understanding of EIF4A3 function in RNA metabolism?

Several cutting-edge technologies and methodologies are poised to significantly enhance our understanding of EIF4A3 biology:

Innovative research approaches:

• CRISPR-based techniques:

  • CRISPR interference (CRISPRi) for tunable repression of EIF4A3 expression

  • CRISPR activation (CRISPRa) for targeted upregulation

  • CRISPR-Cas13 for RNA-level manipulation of EIF4A3 transcripts

  • CRISPR base/prime editing for introducing specific mutations to study structure-function relationships

• Advanced RNA-protein interaction methodologies:

  • CLIP-seq (crosslinking immunoprecipitation followed by sequencing) to map EIF4A3-RNA interactions at nucleotide resolution

  • Hi-CLIP to identify long-range RNA interactions mediated by EIF4A3

  • Proximity labeling techniques (BioID, APEX) to identify spatially-resolved interaction partners

• Single-cell approaches:

  • Single-cell RNA-seq to examine cell-to-cell variability in splicing patterns after EIF4A3 manipulation

  • Spatial transcriptomics to map EIF4A3-dependent alternative splicing in tissue contexts

  • Live-cell imaging of fluorescently-tagged EIF4A3 to track dynamic subcellular localization

• Structural biology advancements:

  • Cryo-EM studies of EIF4A3 within the exon junction complex

  • Single-molecule FRET to analyze conformational changes during RNA binding

  • In-cell NMR to study EIF4A3 structural dynamics in the native cellular environment

• Translational research directions:

  • Development of small molecule inhibitors targeting EIF4A3 helicase activity

  • Cancer-specific splicing signatures as biomarkers

  • Therapeutic approaches targeting EIF4A3-dependent oncogenic splice variants

These emerging approaches will help resolve longstanding questions about the context-specific roles of EIF4A3 in RNA metabolism and may reveal novel therapeutic opportunities for diseases associated with dysregulated RNA processing.

How can I design experiments to investigate the relationship between EIF4A3 and long non-coding RNAs in disease contexts?

Investigating interactions between EIF4A3 and long non-coding RNAs (lncRNAs) requires specialized experimental approaches:

Comprehensive experimental strategy:

• Identification of interacting lncRNAs:

  • Perform RNA immunoprecipitation (RIP) using validated EIF4A3 antibodies (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

  • Follow with RNA-seq (RIP-seq) to identify bound lncRNAs

  • Validate top candidates using RIP-qPCR with specific primers

  • Map binding sites using CLIP-seq or similar techniques

• Functional analysis of interactions:

  • Deplete specific lncRNAs using antisense oligonucleotides or CRISPR-Cas13

  • Assess effects on EIF4A3 localization, protein interactions, and splicing activity

  • Examine if disease-associated lncRNAs affect EIF4A3 recruitment to specific mRNA targets

  • Create truncation mutants of lncRNAs to map EIF4A3 binding domains

• Disease-relevant models:

  • Compare lncRNA-EIF4A3 interactions between normal and disease tissues/cells

  • Utilize patient-derived samples to validate findings in primary cells

  • Develop disease-specific organoid models to study interactions in 3D tissue context

  • Analyze publicly available cancer datasets (TCGA) for correlations between EIF4A3 and lncRNA expression

• Mechanistic studies:

  • Determine if lncRNAs act as scaffolds, guides, or decoys for EIF4A3

  • Investigate competition between lncRNAs and mRNAs for EIF4A3 binding

  • Examine effects on post-translational modifications of EIF4A3

  • Assess impact on EIF4A3's ATPase or helicase activities

• Therapeutic potential:

  • Design antisense oligonucleotides to disrupt specific lncRNA-EIF4A3 interactions

  • Test effects of disrupting these interactions on disease phenotypes

  • Evaluate potential as biomarkers for patient stratification

Recent molecular biology studies have demonstrated that EIF4A3 can be recruited by lncRNAs to regulate specific protein expression in tumors, though the underlying mechanisms remain incompletely understood . This emerging area offers significant potential for discovering novel regulatory networks and therapeutic targets.